Ask AI
Treatment of HER2pos GEA and BTC
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

Released: October 14, 2025

Activity

Progress
1
Course Completed

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:
•    Brief overview of BTC and GEA
•    Approved HER2-directed therapies for BTC and GEA and their mechanisms of action
•    Efficacy and toxicities of the approved agents and optimal management strategies
•    Key ongoing trials of HER2-directed therapies in BTC and GEA
•    Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA